drugset / Trial / NCT02923583

Assessment of Pharmacokinetics (PK) and Safety of M834 and Orencia ®, in Healthy Subjects

NCT02923583

Phase 1 Completed 243 enrolled Momenta Pharmaceuticals, Inc. Mylan · collab
RandomizedParallel-groupDouble-blindBasic science

Summary

The purpose of this study is assess the pharmacokinetics and safety of M834 and Orencia ® following administration of a single-dose in healthy volunteers.

Timeline

Start
2016-10
Primary completion
2017-07-21
Completion
2017-07-21

Drugs

EvaluationDrugModalityDoseRoute
Comparator Abatacept Other / unclassified
Subject M834 Protein / enzyme biologic

Indications

No indication recorded.